A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy

NCT07342517 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped This study has been incorporated into the Relmada REL-NDV01-303 study.

Conditions

Bladder (Urothelial, Transitional Cell) Cancer
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
Urothelial Carcinoma Bladder
Urothelial Carcinoma Recurrent
Urologic Cancer

Interventions

DRUG: NDV-01 (sustained-release gemcitabine-docetaxel)

Sponsor

Relmada Therapeutics, Inc.